SANA

SEC source: 0001562180-24-004842 · primarydocument.xml · derivative · entry 1

Seitz Michelle · CIK 0001836301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,278

Underlying: Common Stock · 54,278 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

SEC source: 0001562180-24-005721 · primarydocument.xml · derivative · entry 1

Wilderotter Mary Agnes · CIK 0001180610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-05

F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

SEC source: 0001562180-24-005715 · primarydocument.xml · derivative · entry 1

Bilenker Joshua H. · CIK 0001612312 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-05

F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

SEC source: 0001562180-24-005718 · primarydocument.xml · derivative · entry 1

Cole Douglas G. · CIK 0001486373 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-05

F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

SEC source: 0001562180-24-005716 · primarydocument.xml · derivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-05

F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

SEC source: 0001562180-24-005722 · primarydocument.xml · derivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-05

F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

SEC source: 0001562180-24-005724 · primarydocument.xml · derivative · entry 1

Yang Patrick Y · CIK 0001309988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-05

F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

SEC source: 0001562180-24-005723 · primarydocument.xml · derivative · entry 1

Mulligan Richard · CIK 0001376247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-05

F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

SEC source: 0001562180-24-005719 · primarydocument.xml · derivative · entry 1

REICIN ALISE · CIK 0001757533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-05

F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

SEC source: 0001562180-24-005720 · primarydocument.xml · derivative · entry 1

Seitz Michelle · CIK 0001836301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-05

F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

SEC source: 0001562180-24-003354 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,779,640

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-24-002538 · primarydocument.xml · nonDerivative · entry 1

Yang Patrick Y · CIK 0001309988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,250

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.44 to $9.49, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-002480 · primarydocument.xml · derivative · entry 2

WILLIAMS DOUGLAS E · CIK 0001184847 · EVP & President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 301,875

Underlying: Common Stock · 301,875 shares

Expires 2034-03-06

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-24-002480 · primarydocument.xml · derivative · entry 1

WILLIAMS DOUGLAS E · CIK 0001184847 · EVP & President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,083

Underlying: Common Stock · 67,083 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-24-002474 · primarydocument.xml · derivative · entry 2

Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,750

Underlying: Common Stock · 198,750 shares

Expires 2034-03-06

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-24-002474 · primarydocument.xml · derivative · entry 1

Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,167

Underlying: Common Stock · 44,167 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-24-002479 · primarydocument.xml · derivative · entry 2

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 900,000

Underlying: Common Stock · 900,000 shares

Expires 2034-03-06

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-24-002479 · primarydocument.xml · derivative · entry 1

Harr Steve · CIK 0001627387 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-24-002477 · primarydocument.xml · derivative · entry 2

Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,750

Underlying: Common Stock · 168,750 shares

Expires 2034-03-06

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-24-002477 · primarydocument.xml · derivative · entry 1

Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-24-002476 · primarydocument.xml · derivative · entry 2

Hardy Nathan · CIK 0001830053 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 301,875

Underlying: Common Stock · 301,875 shares

Expires 2034-03-06

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0001562180-24-002476 · primarydocument.xml · derivative · entry 1

Hardy Nathan · CIK 0001830053 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,083

Underlying: Common Stock · 67,083 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

SEC source: 0000950170-24-015185 · ownership.xml · derivative · entry 1

Flagship Pioneering Inc. · CIK 0001400240 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Pioneering Fund VII, L.P.

Disclosed balance after: 2,727,272

Underlying: Common Stock · 2,727,272 shares

Expires not disclosed

F1 · kind: On February 12, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants to purchase 2,727,272 shares of Common Stock (the "Pre-Funded Warrants") at a purchase price of $5.4999 per Pre-Funded Warrant. The Pre-Funded Warrants do not have an expiration date.

F1 · derivative.expiration_date: On February 12, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants to purchase 2,727,272 shares of Common Stock (the "Pre-Funded Warrants") at a purchase price of $5.4999 per Pre-Funded Warrant. The Pre-Funded Warrants do not have an expiration date.

F2 · ownership.nature: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001062993-24-002840 · form4.xml · nonDerivative · entry 4

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 12,446,022

F5 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.

F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0001062993-24-002840 · form4.xml · nonDerivative · entry 3

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 12,446,022

F4 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.

F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0001062993-24-002840 · form4.xml · nonDerivative · entry 1

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner

ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner

ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner

ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 10,667,387

F1 · ownership.nature: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.

F3 · ownership.nature: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein.

SEC source: 0001062993-24-002841 · form4.xml · nonDerivative · entry 4

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 12,446,022

F5 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.

F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0001062993-24-002841 · form4.xml · nonDerivative · entry 3

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 12,446,022

F4 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.

F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.

SEC source: 0001062993-24-002841 · form4.xml · nonDerivative · entry 1

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Burow Kristina · CIK 0001569248 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 10,667,387

F1 · ownership.nature: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.

F3 · ownership.nature: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein.

SEC source: 0001062993-24-002842 · form4.xml · nonDerivative · entry 4

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 12,446,022

F5 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.

F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the other AVP X Committee Members have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein.

F7 · ownership.nature: The Reporting Person is also an AVP IX MD and an AVP X Committee Member and may be deemed to beneficially own the shares held by ARCH IX, ARCH IX Overage, ARCH X, and ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.

SEC source: 0001062993-24-002842 · form4.xml · nonDerivative · entry 3

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 12,446,022

F4 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.

F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the other AVP X Committee Members have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein.

F7 · ownership.nature: The Reporting Person is also an AVP IX MD and an AVP X Committee Member and may be deemed to beneficially own the shares held by ARCH IX, ARCH IX Overage, ARCH X, and ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.

SEC source: 0001062993-24-002842 · form4.xml · nonDerivative · entry 1

NELSEN ROBERT · CIK 0001219042 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 10,667,387

F1 · ownership.nature: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.

F3 · ownership.nature: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. In addition to the Reporting Person, Keith Crandell and Clinton Bybee are also managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the other AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to to the extent of any pecuniary interest therein

F7 · ownership.nature: The Reporting Person is also an AVP IX MD and an AVP X Committee Member and may be deemed to beneficially own the shares held by ARCH IX, ARCH IX Overage, ARCH X, and ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.

SEC source: 0001562180-24-000341 · primarydocument.xml · nonDerivative · entry 1

Wilderotter Mary Agnes · CIK 0001180610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,106

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-24-000342 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,776,866

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-23-008445 · primarydocument.xml · nonDerivative · entry 1

Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 867,455

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021, as modified on April 11, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.93 to $4.10, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-23-007553 · primarydocument.xml · derivative · entry 1

WILLIAMS DOUGLAS E · CIK 0001184847 · EVP & President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

F2 · derivative.expiration_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

SEC source: 0001562180-23-007547 · primarydocument.xml · derivative · entry 1

Hardy Nathan · CIK 0001830053 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

F2 · derivative.expiration_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

SEC source: 0001562180-23-007550 · primarydocument.xml · derivative · entry 1

Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

F2 · derivative.expiration_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.

SEC source: 0001562180-23-007237 · primarydocument.xml · nonDerivative · entry 1

Wilderotter Mary Agnes · CIK 0001180610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,636

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-23-007236 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,771,965

F1 · shares: Consists of fully vested restricted stock units for which the Reporting Person has elected to defer settlement until January 1, 2024 pursuant to Sana Biotechnology, Inc.'s Non-Employee Director Compensation Program.

SEC source: 0000899243-23-019165 · doc4.xml · nonDerivative · entry 6

Flagship Pioneering Inc. · CIK 0001400240 · 10% owner

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner

Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner

Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner

Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Pioneering Fund VI General Partner LLC

Disclosed balance after: 0

F7 · kind: On September 13, 2023, Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI") distributed in-kind to its limited partners and sole general partner, Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP"), pro rata and without consideration, 2,431,281 shares of the Issuer's common stock. Flagship Fund VI GP, in turn, distributed in-kind to its members, pro rata and without consideration, the 70,813 shares it received from Flagship Fund VI. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F7 · price: On September 13, 2023, Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI") distributed in-kind to its limited partners and sole general partner, Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP"), pro rata and without consideration, 2,431,281 shares of the Issuer's common stock. Flagship Fund VI GP, in turn, distributed in-kind to its members, pro rata and without consideration, the 70,813 shares it received from Flagship Fund VI. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F9 · ownership.nature: Represents shares held directly by Flagship Fund VI GP. Each of the reporting persons except Flagship Fund VI GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-019165 · doc4.xml · nonDerivative · entry 5

Flagship Pioneering Inc. · CIK 0001400240 · 10% owner

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner

Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner

Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner

Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Pioneering Fund VI, L.P.

Disclosed balance after: 7,293,841

F7 · kind: On September 13, 2023, Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI") distributed in-kind to its limited partners and sole general partner, Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP"), pro rata and without consideration, 2,431,281 shares of the Issuer's common stock. Flagship Fund VI GP, in turn, distributed in-kind to its members, pro rata and without consideration, the 70,813 shares it received from Flagship Fund VI. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F7 · price: On September 13, 2023, Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI") distributed in-kind to its limited partners and sole general partner, Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP"), pro rata and without consideration, 2,431,281 shares of the Issuer's common stock. Flagship Fund VI GP, in turn, distributed in-kind to its members, pro rata and without consideration, the 70,813 shares it received from Flagship Fund VI. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F8 · ownership.nature: Represents shares held directly by Flagship Fund VI. Flagship Fund VI GP is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-019165 · doc4.xml · nonDerivative · entry 4

Flagship Pioneering Inc. · CIK 0001400240 · 10% owner

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner

Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner

Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner

Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund V General Partner LLC

Disclosed balance after: 0

F3 · kind: On September 13, 2023, Flagship Ventures Fund V, L.P. ("Flagship Fund V") and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") distributed in-kind to their respective limited partners and sole general partner, Flagship Ventures Fund V General Partner, LLC ("Flagship Fund V GP"), pro rata and without consideration, 4,926,378 shares and 345,069 shares, respectively, of the Issuer's common stock. Flagship Fund V GP, in turn, distributed in-kind to its members, pro rata and without consideration, the aggregate of 1,181,745 shares it received from Flagship Fund V and Flagship Fund V Rx. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F3 · price: On September 13, 2023, Flagship Ventures Fund V, L.P. ("Flagship Fund V") and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") distributed in-kind to their respective limited partners and sole general partner, Flagship Ventures Fund V General Partner, LLC ("Flagship Fund V GP"), pro rata and without consideration, 4,926,378 shares and 345,069 shares, respectively, of the Issuer's common stock. Flagship Fund V GP, in turn, distributed in-kind to its members, pro rata and without consideration, the aggregate of 1,181,745 shares it received from Flagship Fund V and Flagship Fund V Rx. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F6 · ownership.nature: Represents shares held directly by Flagship Fund V GP. Each of the reporting persons except Flagship Fund V GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-019165 · doc4.xml · nonDerivative · entry 3

Flagship Pioneering Inc. · CIK 0001400240 · 10% owner

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner

Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner

Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner

Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship V VentureLabs Rx Fund, L.P.

Disclosed balance after: 1,035,208

F3 · kind: On September 13, 2023, Flagship Ventures Fund V, L.P. ("Flagship Fund V") and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") distributed in-kind to their respective limited partners and sole general partner, Flagship Ventures Fund V General Partner, LLC ("Flagship Fund V GP"), pro rata and without consideration, 4,926,378 shares and 345,069 shares, respectively, of the Issuer's common stock. Flagship Fund V GP, in turn, distributed in-kind to its members, pro rata and without consideration, the aggregate of 1,181,745 shares it received from Flagship Fund V and Flagship Fund V Rx. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F3 · price: On September 13, 2023, Flagship Ventures Fund V, L.P. ("Flagship Fund V") and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") distributed in-kind to their respective limited partners and sole general partner, Flagship Ventures Fund V General Partner, LLC ("Flagship Fund V GP"), pro rata and without consideration, 4,926,378 shares and 345,069 shares, respectively, of the Issuer's common stock. Flagship Fund V GP, in turn, distributed in-kind to its members, pro rata and without consideration, the aggregate of 1,181,745 shares it received from Flagship Fund V and Flagship Fund V Rx. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F5 · ownership.nature: Represents shares held directly by Flagship Fund V Rx. Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-019165 · doc4.xml · nonDerivative · entry 2

Flagship Pioneering Inc. · CIK 0001400240 · 10% owner

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner

Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner

Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner

Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship Ventures Fund V, L.P.

Disclosed balance after: 8,057,470

F3 · kind: On September 13, 2023, Flagship Ventures Fund V, L.P. ("Flagship Fund V") and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") distributed in-kind to their respective limited partners and sole general partner, Flagship Ventures Fund V General Partner, LLC ("Flagship Fund V GP"), pro rata and without consideration, 4,926,378 shares and 345,069 shares, respectively, of the Issuer's common stock. Flagship Fund V GP, in turn, distributed in-kind to its members, pro rata and without consideration, the aggregate of 1,181,745 shares it received from Flagship Fund V and Flagship Fund V Rx. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F3 · price: On September 13, 2023, Flagship Ventures Fund V, L.P. ("Flagship Fund V") and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") distributed in-kind to their respective limited partners and sole general partner, Flagship Ventures Fund V General Partner, LLC ("Flagship Fund V GP"), pro rata and without consideration, 4,926,378 shares and 345,069 shares, respectively, of the Issuer's common stock. Flagship Fund V GP, in turn, distributed in-kind to its members, pro rata and without consideration, the aggregate of 1,181,745 shares it received from Flagship Fund V and Flagship Fund V Rx. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F4 · balance_after: Represents shares held directly by Flagship Fund V. Includes 2,240,555 shares received in the distribution-in-kind from VentureLabs V described in footnote (1) above. Flagship V GP is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F4 · ownership.nature: Represents shares held directly by Flagship Fund V. Includes 2,240,555 shares received in the distribution-in-kind from VentureLabs V described in footnote (1) above. Flagship V GP is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-23-019165 · doc4.xml · nonDerivative · entry 1

Flagship Pioneering Inc. · CIK 0001400240 · 10% owner

Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner

Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner

Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner

Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner

Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner

Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner

Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner

AFEYAN NOUBAR · CIK 0001222012 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Flagship VentureLabs V, LLC

Disclosed balance after: 8,615,337

F1 · kind: On September 13, 2023, Flagship VentureLabs V LLC ("VentureLabs V") distributed in-kind to its members, pro rata and without consideration, 2,825,989 shares of the Issuer's common stock. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: On September 13, 2023, Flagship VentureLabs V LLC ("VentureLabs V") distributed in-kind to its members, pro rata and without consideration, 2,825,989 shares of the Issuer's common stock. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.nature: Represents shares held directly by VentureLabs V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001562180-23-005766 · primarydocument.xml · nonDerivative · entry 1

Wilderotter Mary Agnes · CIK 0001180610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,559

F1 · shares: Consists of fully vested restricted stock units.

SEC source: 0001562180-23-005765 · primarydocument.xml · nonDerivative · entry 1

Bishop Hans Edgar · CIK 0001480212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,765,040

F1 · shares: Consists of fully vested restricted stock units for which the Reporting Person has elected to defer settlement until January 1, 2024 pursuant to Sana Biotechnology, Inc.'s Non-Employee Director Compensation Program.

SEC source: 0001562180-23-005028 · primarydocument.xml · derivative · entry 1

Wilderotter Mary Agnes · CIK 0001180610 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023.

SEC source: 0001562180-23-005030 · primarydocument.xml · derivative · entry 1

Bilenker Joshua H. · CIK 0001612312 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023.